OncoMatch/Clinical Trials/NCT07219212
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Is NCT07219212 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including JNJ-90301900 and Cisplatin for squamous cell carcinoma of head and neck.
Treatment: JNJ-90301900 · Cisplatin — This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CDKN2A p16 negative (negative)
Disease stage
Required: Stage III, IVA, IVB
Excluded: Stage 0, I, II, IVC
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Mayo Clinic · Jacksonville, Florida
- Moffit Cancer center · Tampa, Florida
- Emory University · Atlanta, Georgia
- Montefiore Medical Center · The Bronx, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify